LLY

718.42

-1.22%↓

JNJ

153.11

-0.26%↓

ABBV

183.43

+0.77%↑

NVO

68.39

+0.22%↑

UNH

297.77

-1.73%↓

LLY

718.42

-1.22%↓

JNJ

153.11

-0.26%↓

ABBV

183.43

+0.77%↑

NVO

68.39

+0.22%↑

UNH

297.77

-1.73%↓

LLY

718.42

-1.22%↓

JNJ

153.11

-0.26%↓

ABBV

183.43

+0.77%↑

NVO

68.39

+0.22%↑

UNH

297.77

-1.73%↓

LLY

718.42

-1.22%↓

JNJ

153.11

-0.26%↓

ABBV

183.43

+0.77%↑

NVO

68.39

+0.22%↑

UNH

297.77

-1.73%↓

LLY

718.42

-1.22%↓

JNJ

153.11

-0.26%↓

ABBV

183.43

+0.77%↑

NVO

68.39

+0.22%↑

UNH

297.77

-1.73%↓

Search

CEL-SCI Corp

Open

SectorGezondheidszorg

2.53 -44.88

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.32

Max

4.92

Belangrijke statistieken

By Trading Economics

Inkomsten

501K

-6.6M

EPS

-0.096

EBITDA

-225K

-5.9M

Dividenden

By Dow Jones

Volgende Winsten

14 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-4.2M

17M

Vorige openingsprijs

47.41

Vorige sluitingsprijs

2.53

Nieuwssentiment

By Acuity

58%

42%

334 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

CEL-SCI Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 mei 2025, 23:25 UTC

Populaire aandelen

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 mei 2025, 21:57 UTC

Acquisities, Fusies, Overnames

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 mei 2025, 21:29 UTC

Acquisities, Fusies, Overnames

Millicom to Acquire Telefónica's Operations in Uruguay

21 mei 2025, 21:01 UTC

Belangrijke Marktbewegers

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 mei 2025, 23:49 UTC

Marktinformatie

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 mei 2025, 23:37 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 mei 2025, 23:33 UTC

Acquisities, Fusies, Overnames

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mei 2025, 23:32 UTC

Acquisities, Fusies, Overnames

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mei 2025, 23:32 UTC

Acquisities, Fusies, Overnames

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mei 2025, 23:32 UTC

Marktinformatie
Acquisities, Fusies, Overnames

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 mei 2025, 23:31 UTC

Acquisities, Fusies, Overnames

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 mei 2025, 23:30 UTC

Acquisities, Fusies, Overnames

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 mei 2025, 23:30 UTC

Acquisities, Fusies, Overnames

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 mei 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 mei 2025, 23:28 UTC

Winsten

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 mei 2025, 23:27 UTC

Winsten

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 mei 2025, 23:26 UTC

Winsten

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 mei 2025, 23:26 UTC

Winsten

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 mei 2025, 23:26 UTC

Winsten

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 mei 2025, 23:23 UTC

Acquisities, Fusies, Overnames

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mei 2025, 23:22 UTC

Top Nieuws

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

21 mei 2025, 23:22 UTC

Acquisities, Fusies, Overnames

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mei 2025, 23:20 UTC

Acquisities, Fusies, Overnames

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mei 2025, 23:18 UTC

Acquisities, Fusies, Overnames

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 mei 2025, 23:04 UTC

Top Nieuws

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

21 mei 2025, 21:46 UTC

Top Nieuws

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

21 mei 2025, 21:42 UTC

Top Nieuws
Acquisities, Fusies, Overnames

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 mei 2025, 21:14 UTC

Acquisities, Fusies, Overnames

Millicom to Acquire Telefónica's Ops in Uruguay

21 mei 2025, 21:07 UTC

Top Nieuws

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 mei 2025, 21:06 UTC

Acquisities, Fusies, Overnames

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Peer Vergelijking

Prijswijziging

CEL-SCI Corp Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Technische score

By Trading Central

N/A / 0.2494Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

334 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

$

Over CEL-SCI Corp

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.